Table of contents

Original research

• S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study (9 March, 2017)

  Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
• Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma (27 April, 2017)

  Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
• Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI) (9 March, 2017)

  Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
• Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study (15 March, 2017)

  Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
• Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy (12 April, 2017)

  Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
• Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer (11 April, 2017)

  Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
• Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab (28 March, 2017)

  Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
• Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey (27 April, 2017)

  Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
• Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study (14 March, 2017)

  Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti